Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals (JAZZ) raised its revenue estimate for Ziihera to $3B-$5B, citing potential expansion in multiple cancer types. The company expects Ziihera to become a first-line standard of care for HER2-positive gastroesophageal adenocarcinoma. Jazz also announced pipeline expansions in epilepsy and sleep-wake disorders, including new clinical trials and formulations.

Jazz Pharmaceuticals (JAZZ) acquired Actio Biosciences for $820M, with potential $500M in milestone payments, to gain control of ABS-1230, a treatment for rare childhood epilepsy. Jazz reported Q2 revenue of $1.2B, up 16% YoY, and raised 2026 guidance to $4.6B-$4.75B. The company also acquired Chimerix for $944M in 2025. ABS-1230 is in Phase 1b/2a trials, with early results showing seizure reductions. Jazz trades at ~9.5x forward earnings, offering growth potential but with clinical risks.

Jazz Pharmaceuticals (JAZZ) acquired Actio Biosciences for $820M, adding epilepsy drug ABS-1230 to its pipeline. Jazz reported record Q2 revenue of $1.2B and raised 2026 guidance to $4.6B-$4.75B. The deal adds to existing debt, and ABS-1230 is in early clinical stages. Jazz's shares trade at a forward P/E of 11.03.

Jazz Pharmaceuticals (JAZZ) completed its $820M acquisition of Actio Biosciences, adding ABS-1230, a clinical-stage therapy for KCNT1-related epilepsy. Actio is now a subsidiary, strengthening Jazz's epilepsy pipeline. ABS-1230 has FDA designations and showed seizure reduction in early trials. Jazz plans to advance the therapy's development.

UBS raised its price target for Jazz Pharmaceuticals (JAZZ) to $337 from $315, citing the recent approval of Ziihera and potential for additional indications. The stock has surged 87% over the past year. Other analysts have also increased their price targets, with Jazz's management raising Ziihera's peak sales outlook to $3B-$5B.

S&P Global Ratings upgraded Jazz Pharmaceuticals' senior secured debt to 'BB+' from 'BB' and assigned a 'BB+' rating to a proposed $1.9B term loan. The company expects strong cash flow and revenue growth, with recent FDA approvals and acquisitions. Jazz's leverage is 1.8x, providing a cushion against rating thresholds. The company plans to use proceeds for general purposes and share repurchases.